Solutions - Page 17

The German CDMO devoted 480 million euros ($574.3 million) to the first construction phase for a new plant in Saarlouis, Germany, which is expected to be operational by 2031.

With Cellares preparing to begin commercial-stage production in 2027, the California-based cell therapy contract manufacturer has taken a major step toward that goal, raising $257 million in a series D round.

Biosynthesis specialist Antheia has topped off its series C funding with a second close, adding $24 million more to its haul. The financing lift brings Antheia’s total funding over the past year

China’s National Medical Products Administration suspended the import, sale and use of Sun’s rivastigmine hydrogen tartrate capsules after a virtual site inspection uncovered manufacturing shortfalls.

Siegfried has signed agreements to acquire the controlled drug substance businesses of the Noramco Group and Extractas Bioscience. With the deals, Siegfried gains API sites in Wilmington, Delaware; Athens, Georgia; and Australia.

Catalent made a series of deals early this decade to build up its presence in Gosselies. Now, it’s planning to wind down cell therapy manufacturing operations in the town.

Juggling a mix of customer demand and new regulations, Recipharm has built out a new facility in Bengaluru, India, to produce nonbacterial beta-lactam tablets. By commissioning the plant, Recipharm says it has

ST Pharm has struck a $56 million deal with an undisclosed U.S.-based biotech to produce active pharmaceutical ingredients (APIs) for a new oligonucleotide treatment. The Korean CDMO revealed the contract Friday in

While the threat of U.S. import tariffs prompted a surge in drug production last year, that output is slated to slow across multiple geographies in 2026, according to a new report from

Curia Global is laying off 81 employees as part of its plan to shut down its drug product development and manufacturing facility in Burlington, Massachusetts, according to a Worker Adjustment and Retraining